PureTech subsidiary licences microbiome-based therapy
PureTech Health subsidiary Commense Inc has licensed a microbiome-based therapy to prevent asthma and other allergic diseases from the University of British Columbia.
PURETECH HEALTH
£1.54
17:35 27/09/24
2.66%
£0.04
"This live biotherapeutic product bolsters Commense's pipeline of novel therapeutic programs designed to nurture a healthy microbiome early in life," the company said.